288 related articles for article (PubMed ID: 32094149)
1. Imipridone Anticancer Compounds Ectopically Activate the ClpP Protease and Represent a New Scaffold for Antibiotic Development.
Jacques S; van der Sloot AM; C Huard C; Coulombe-Huntington J; Tsao S; Tollis S; Bertomeu T; Culp EJ; Pallant D; Cook MA; Bonneil E; Thibault P; Wright GD; Tyers M
Genetics; 2020 Apr; 214(4):1103-1120. PubMed ID: 32094149
[TBL] [Abstract][Full Text] [Related]
2. Cell Division Protein FtsZ Is Unfolded for N-Terminal Degradation by Antibiotic-Activated ClpP.
Silber N; Pan S; Schäkermann S; Mayer C; Brötz-Oesterhelt H; Sass P
mBio; 2020 Jun; 11(3):. PubMed ID: 32605984
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues.
Graves PR; Aponte-Collazo LJ; Fennell EMJ; Graves AC; Hale AE; Dicheva N; Herring LE; Gilbert TSK; East MP; McDonald IM; Lockett MR; Ashamalla H; Moorman NJ; Karanewsky DS; Iwanowicz EJ; Holmuhamedov E; Graves LM
ACS Chem Biol; 2019 May; 14(5):1020-1029. PubMed ID: 31021596
[TBL] [Abstract][Full Text] [Related]
4.
Brown Gandt A; Griffith EC; Lister IM; Billings LL; Han A; Tangallapally R; Zhao Y; Singh AP; Lee RE; LaFleur MD
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784838
[TBL] [Abstract][Full Text] [Related]
5. The antibiotic ADEP reprogrammes ClpP, switching it from a regulated to an uncontrolled protease.
Kirstein J; Hoffmann A; Lilie H; Schmidt R; Rübsamen-Waigmann H; Brötz-Oesterhelt H; Mogk A; Turgay K
EMBO Mol Med; 2009 Apr; 1(1):37-49. PubMed ID: 20049702
[TBL] [Abstract][Full Text] [Related]
6. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
Prabhu VV; Morrow S; Rahman Kawakibi A; Zhou L; Ralff M; Ray J; Jhaveri A; Ferrarini I; Lee Y; Parker C; Zhang Y; Borsuk R; Chang WI; Honeyman JN; Tavora F; Carneiro B; Raufi A; Huntington K; Carlsen L; Louie A; Safran H; Seyhan AA; Tarapore RS; Schalop L; Stogniew M; Allen JE; Oster W; El-Deiry WS
Neoplasia; 2020 Dec; 22(12):725-744. PubMed ID: 33142238
[TBL] [Abstract][Full Text] [Related]
7. Dysregulation of bacterial proteolytic machinery by a new class of antibiotics.
Brötz-Oesterhelt H; Beyer D; Kroll HP; Endermann R; Ladel C; Schroeder W; Hinzen B; Raddatz S; Paulsen H; Henninger K; Bandow JE; Sahl HG; Labischinski H
Nat Med; 2005 Oct; 11(10):1082-7. PubMed ID: 16200071
[TBL] [Abstract][Full Text] [Related]
8. Functional Characterisation of ClpP Mutations Conferring Resistance to Acyldepsipeptide Antibiotics in Firmicutes.
Malik IT; Pereira R; Vielberg MT; Mayer C; Straetener J; Thomy D; Famulla K; Castro H; Sass P; Groll M; Brötz-Oesterhelt H
Chembiochem; 2020 Jul; 21(14):1997-2012. PubMed ID: 32181548
[TBL] [Abstract][Full Text] [Related]
9. ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer.
Ferrarini I; Louie A; Zhou L; El-Deiry WS
Mol Cancer Ther; 2021 Sep; 20(9):1572-1583. PubMed ID: 34224362
[TBL] [Abstract][Full Text] [Related]
10. Ureadepsipeptides as ClpP Activators.
Griffith EC; Zhao Y; Singh AP; Conlon BP; Tangallapally R; Shadrick WR; Liu J; Wallace MJ; Yang L; Elmore JM; Li Y; Zheng Z; Miller DJ; Cheramie MN; Lee RB; LaFleur MD; Lewis K; Lee RE
ACS Infect Dis; 2019 Nov; 5(11):1915-1925. PubMed ID: 31588734
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of imipridones in targeting mitochondrial metabolism in cancer cells.
Bonner ER; Waszak SM; Grotzer MA; Mueller S; Nazarian J
Neuro Oncol; 2021 Apr; 23(4):542-556. PubMed ID: 33336683
[TBL] [Abstract][Full Text] [Related]
12. Structures of ClpP in complex with acyldepsipeptide antibiotics reveal its activation mechanism.
Lee BG; Park EY; Lee KE; Jeon H; Sung KH; Paulsen H; Rübsamen-Schaeff H; Brötz-Oesterhelt H; Song HK
Nat Struct Mol Biol; 2010 Apr; 17(4):471-8. PubMed ID: 20305655
[TBL] [Abstract][Full Text] [Related]
13. Generation of Lasso Peptide-Based ClpP Binders.
Malik IT; Hegemann JD; Brötz-Oesterhelt H
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008890
[TBL] [Abstract][Full Text] [Related]
14. A simple fragment of cyclic acyldepsipeptides is necessary and sufficient for ClpP activation and antibacterial activity.
Carney DW; Compton CL; Schmitz KR; Stevens JP; Sauer RT; Sello JK
Chembiochem; 2014 Oct; 15(15):2216-20. PubMed ID: 25212124
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality.
Ishizawa J; Zarabi SF; Davis RE; Halgas O; Nii T; Jitkova Y; Zhao R; St-Germain J; Heese LE; Egan G; Ruvolo VR; Barghout SH; Nishida Y; Hurren R; Ma W; Gronda M; Link T; Wong K; Mabanglo M; Kojima K; Borthakur G; MacLean N; Ma MCJ; Leber AB; Minden MD; Houry W; Kantarjian H; Stogniew M; Raught B; Pai EF; Schimmer AD; Andreeff M
Cancer Cell; 2019 May; 35(5):721-737.e9. PubMed ID: 31056398
[TBL] [Abstract][Full Text] [Related]
16. Phenyl Esters Are Potent Inhibitors of Caseinolytic Protease P and Reveal a Stereogenic Switch for Deoligomerization.
Hackl MW; Lakemeyer M; Dahmen M; Glaser M; Pahl A; Lorenz-Baath K; Menzel T; Sievers S; Böttcher T; Antes I; Waldmann H; Sieber SA
J Am Chem Soc; 2015 Jul; 137(26):8475-83. PubMed ID: 26083639
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.
Wagner J; Kline CL; Ralff MD; Lev A; Lulla A; Zhou L; Olson GL; Nallaganchu BR; Benes CH; Allen JE; Prabhu VV; Stogniew M; Oster W; El-Deiry WS
Cell Cycle; 2017 Oct; 16(19):1790-1799. PubMed ID: 28489985
[TBL] [Abstract][Full Text] [Related]
18. Antibiotic Acyldepsipeptides Stimulate the
Reinhardt L; Thomy D; Lakemeyer M; Westermann LM; Ortega J; Sieber SA; Sass P; Brötz-Oesterhelt H
mBio; 2022 Dec; 13(6):e0141322. PubMed ID: 36286522
[TBL] [Abstract][Full Text] [Related]
19. The development of small-molecule modulators for ClpP protease activity.
Ye F; Li J; Yang CG
Mol Biosyst; 2016 Dec; 13(1):23-31. PubMed ID: 27831584
[TBL] [Abstract][Full Text] [Related]
20. Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia.
Nii T; Prabhu VV; Ruvolo V; Madhukar N; Zhao R; Mu H; Heese L; Nishida Y; Kojima K; Garnett MJ; McDermott U; Benes CH; Charter N; Deacon S; Elemento O; Allen JE; Oster W; Stogniew M; Ishizawa J; Andreeff M
Leukemia; 2019 Dec; 33(12):2805-2816. PubMed ID: 31127149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
